GENE ONLINE|News &
Checkpoint Inhibitors as Part of Neoadjuvant Therapy in TNBC: Should We Use Them or Not?
Triple-negative breast cancer (TNBC) is a tough nut to crack, being a type of cancer with many mutations. TNBC, which comprises around 15% of breast cancers, carries a high mortality rate, and few treatments improve the odds of survival.
Cancer cells evade the immune system by stimulating immune checkpoints. Several studies have shown that highly mutated cancers may be more sensitive to treatment when checkpoint inhibitors are added in neoadjuvant therapy -- the medication given before the main treatment to shrink the tumor to more manageable levels. However, other studies are more cautious about the clinical benefits of checkpoint inhibition.
Recently at the 2021 ESMO Virtual Congress, experts debated whether or not to use immune checkpoint inhibitors as part of neoadjuvant therapy. The session was chaired by Dr. Sibylle Loibl, CEO of the German Breast Cancer Group, a leading group in breast cancer research.
Cancer cells evade the immune system by stimulating immune checkpoints. Several studies have shown that highly mutated cancers may be more sensitive to treatment when checkpoint inhibitors are added in neoadjuvant therapy -- the medication given before the main treatment to shrink the tumor to more manageable levels. However, other studies are more cautious about the clinical benefits of checkpoint inhibition.
Recently at the 2021 ESMO Virtual Congress, experts debated whether or not to use immune checkpoint inhibitors as part of neoadjuvant therapy. The session was chaired by Dr. Sibylle Loibl, CEO of the German Breast Cancer Group, a leading group in breast cancer research.
GO Prime with only $1.49 now
LATEST
